Pfizer’s arthritis drug can cut death risk in severe COVID-19 patients: Study
Image Credit: shortpedia
An arthritis drug -- Tofacitinib -- developed by US biopharmaceutical Pfizer has shown to be effective in reducing the risk of death or respiratory failure in hospitalised adult patients with COVID-19 pneumonia who were not on ventilation, according to a study. Tofacitinib belongs to a class of drugs called Janus kinase (JAK) inhibitors. It is approved in the US to treat conditions including rheumatoid arthritis, psoriatic arthritis.